scispace - formally typeset
X

Xiaoyuan Chen

Researcher at National University of Singapore

Publications -  1270
Citations -  115993

Xiaoyuan Chen is an academic researcher from National University of Singapore. The author has contributed to research in topics: Photothermal therapy & Medicine. The author has an hindex of 149, co-authored 994 publications receiving 89870 citations. Previous affiliations of Xiaoyuan Chen include Brown University & University of Southern California.

Papers
More filters
Journal ArticleDOI

18F-FPPRGD2 and 18F-FDG PET of Response to Abraxane Therapy

TL;DR: 18F-FPPRGD2 PET is superior to 18F-FDG PET in monitoring early response to treatment, favoring its potential clinical translation and Abraxane-mediated downregulation of integrin αvβ3 expression on tumor endothelial cells can be quantitatively visualized by PET.
Journal ArticleDOI

68Ga-BBN-RGD PET/CT for GRPR and Integrin αvβ3 Imaging in Patients with Breast Cancer.

TL;DR: 68Ga-BBN-RGD PET/CT may be of great value in discerning both primary breast cancers, axillary lymph node metastasis and distant metastases and significant uptake of a new type of dual integrin αvβ3 and GRPR targeting radiotracer in both the primary lesion and the metastases of breast cancer.
Journal ArticleDOI

PEGylated TNF-related apoptosis-inducing ligand (TRAIL) analogues: pharmacokinetics and antitumor effects.

TL;DR: The findings suggest that TRAIL derivatized with PEG of an appropriate M(w) might be useful antitumor agent with protracted activity.
Journal ArticleDOI

Chemical Conjugation of Evans Blue Derivative: A Strategy to Develop Long-Acting Therapeutics through Albumin Binding.

TL;DR: A novel platform for developing long lasting therapeutics by conjugating a small molecular albumin binding moiety, truncated Evans blue, to either peptides or proteins, which has considerable potential to treat type 2 diabetes.
Journal ArticleDOI

Recent Advances in Stimuli-Responsive Platforms for Cancer Immunotherapy.

TL;DR: This Account introduces the recent progress of the group and others on the development of stimuli-responsive platforms for cancer immunotherapy, and summarizes the general chemical design for constructing stimuli- responsive delivery platforms targeting immune targets at distinct locations.